2026 Jennifer A. Pietenpol: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	83	3428	3156	1728	1552	207	38503

Research.com Recognitions

2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Jennifer A. Pietenpol is affiliated with Vanderbilt University Medical Center in the United States. Their research focuses primarily on medicine and biochemistry, genetics, and molecular biology, with a significant emphasis on oncology, molecular biology, cancer research, immunology, and pulmonary and respiratory medicine.

The scientist's main topics of work include:

Cancer Immunotherapy and Biomarkers
Cancer Genomics and Diagnostics
Breast Cancer Treatment Studies
Cancer-related Molecular Pathways
Cancer Cells and Metastasis
Advanced Breast Cancer Therapies
Global Cancer Incidence and Screening

Jennifer A. Pietenpol has contributed to multiple recent research papers, including:

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes, 2021, Nature Communications
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors, 2020, Science Translational Medicine
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer, 2023, Cancer Discovery
Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes, 2021, Nature Communications
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer, 2023, Nature Communications

Frequent co-authors collaborating with Jennifer A. Pietenpol include:

Brian D. Lehmann
Melinda E. Sanders
Paula I. González-Ericsson
Justin M. Balko
Vandana G. Abramson

The scientist's work has been published notably in venues such as:

Cancer Research
Nature Communications
bioRxiv (Cold Spring Harbor Laboratory)
UNC Libraries
Cancer Discovery

Jennifer A. Pietenpol received recognition as a Fellow of the American Association for the Advancement of Science (AAAS) in 2012.

Best Publications

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Brian D. Lehmann;Joshua A. Bauer;Xi Chen;Melinda E. Sanders

5731
Citations
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis

el-Deiry Ws;Harper Jw;O'Connor Pm;O'Connor Pm;Velculescu Ve

2968
Citations
Definition of a consensus binding site for p53.

Wafik S. El-Deiry;Scott E. Kern;Jennifer A. Pietenpol;Kenneth W. Kinzler

2676
Citations
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Jonathan D. Oliner;Jennifer A. Pietenpol;Sam Thiagalingam;Jeno Gyuris

1956
Citations
TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights

Harold L. Moses;Edmund Y. Yang;Jennifer A. Pietenpol

1433
Citations
Oncogenic forms of p53 inhibit p53-regulated gene expression

Scott E. Kern;Jennifer A. Pietenpol;Sam Thiagalingam;Albert Seymour

1290
Citations
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Brian D. Lehmann;Bojana Jovanović;Xi Chen;Monica V. Estrada

1232
Citations
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

Hiroko Masuda;Keith A. Baggerly;Ying Wang;Ya Zhang

802
Citations
TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains

Jennifer A. Pietenpol;Roland W. Stein;Elizabeth Moran;Peter Yaciuk

727
Citations
Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis.

J.A Pietenpol;Z.A Stewart

639
Citations
Sequence-specific transcriptional activation is essential for growth suppression by p53.

Jennifer A. Pietenpol;Takashi Tokino;Sam Thiagalingam;Wafik S. El-Deiry

570
Citations
Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation.

Jennifer A. Pietenpol;Jeffrey T. Holt;Roland W. Stein;Harold L. Moses

570
Citations
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

Justin M. Balko;Jennifer M. Giltnane;Kai Wang;Luis J. Schwarz

526
Citations
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes

Brian D Lehmann;Jennifer A Pietenpol

500
Citations
The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations

Matthew D. Westfall;Deborah J. Mays;Joseph C. Sniezek;Jennifer A. Pietenpol

470
Citations
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling.

Kimberly A. Brown;Jennifer A. Pietenpol;Harold L. Moses

470
Citations
Cell-cycle dysregulation and anticancer therapy

Zoe A Stewart;Matthew D Westfall;Jennifer A Pietenpol

437
Citations
Significance of p63 amplification and overexpression in lung cancer development and prognosis.

Pierre P. Massion;Peter M. Taflan;S. M. Jamshedur Rahman;Pinar Yildiz

424
Citations
Subtyping of triple-negative breast cancer: Implications for therapy

Vandana G. Abramson;Vandana G. Abramson;Brian D. Lehmann;Brian D. Lehmann;Tarah J. Ballinger;Jennifer A. Pietenpol;Jennifer A. Pietenpol

390
Citations
New strategies for triple-negative breast cancer--deciphering the heterogeneity

Ingrid A. Mayer;Vandana G. Abramson;Brian D. Lehmann;Jennifer A. Pietenpol

353
Citations